Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Burkitt Lymphoma 1

Interventions

Rituximab 17Cyclophosphamide 9fludarabine phosphate 8Peripheral Blood Stem Cell Transplantation 7Lenalidomide 6Filgrastim 6Mycophenolic Acid 5ibritumomab tiuxetan 4Whole-Body Irradiation 4Indium 4Everolimus 4Bortezomib 4romidepsin 3Sirolimus 3Etoposide 3Cyclosporine 3temsirolimus 2bazlitoran 2alvocidib 2Tacrolimus 2Radiotherapy 2Prednisone 2Methotrexate 2In Situ Hybridization, Fluorescence 2Ifosfamide 2Gene Expression Profiling 2Carboplatin 2Busulfan 2Biopsy 2Antilymphocyte Serum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Waldenstrom Macroglobulinemia × IL32 protein, human × Clear all
NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
6 enrolled 10 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡